
671OConversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (NEOLAP): Final results of a multicenter randomised phase II AIO trial
Kunzmann, V, Algül, H, Goekkurt, E, Siegler, G M, Martens, U M, Waldschmidt, D, Pelzer, U, Hennes, E, Fuchs, M, Siveke, J, Kullmann, F, Boeck, S, Ettrich, T J, Ferenczy, P, Keller, R, Germer, C-T, SteVolume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz247
Date:
October, 2019
Fichier:
PDF, 89 KB
2019